TIDMABC
RNS Number : 4536C
ABCAM Plc
22 January 2018
22 January 2018
ABCAM PLC
("Abcam" or "the Company")
Abcam Signs Exclusive License Agreement with Roche
-- The product portfolio of Spring Bioscience Corporation to be
licensed to Abcam for research use only (RUO) applications
-- The portfolio includes 243 recombinant rabbit monoclonal antibodies
Abcam (AIM: ABC), a global leader in the supply of life science
research tools, is pleased to announce that it has entered into a
definitive license agreement with Roche. Under the terms of the
agreement Abcam will obtain the exclusive rights to the product
portfolio of Spring Bioscience Corporation ("Spring") in the
research use only (RUO) field of use, comprising a total of
approximately 760 unique products (the "Spring Portfolio"). Roche,
which acquired Spring in 2007, will retain the antibody development
capabilities and rights pertaining to the Spring Portfolio for
internal research, companion diagnostic and IVD uses.
The core portfolio consists of 243 recombinant rabbit monoclonal
antibodies, branded Spring Proprietary Clones (SP Clones), which
have been optimised for immunohistochemistry (IHC). In addition to
the SP Clones, the agreement covers approximately 500 additional
products, predominantly other monoclonal and polyclonal antibodies.
All products will be sold under the Abcam brand, inclusive of SP
branding, and are expected to be available through Abcam.com from
21 February 2018.
Under the terms of the agreement, Abcam has also been granted
exclusive RUO rights for all future products developed by Spring
that Roche requests to be commercialised in the RUO field of use
for an initial period of 10 years and then extendable on mutually
agreeable terms.
Financial terms of the agreement have not been disclosed.
Alan Hirzel, CEO of Abcam, said:
"This agreement represents an exciting step in the ongoing
collaborative and long-term relationship between Abcam and Roche.
By incorporating the Spring Bioscience antibodies into our
portfolio, we will be able to better assist our customers,
providing them with more products for their most important targets,
faster. Abcam is excited to partner with Spring Bioscience,
commonly recognised as a leading manufacturer of IHC antibodies,
furthering Abcam's mission to provide customers with the highest
quality recombinant antibodies for their research."
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Alan Hirzel, Chief Executive Officer
Gavin Wood, Chief Financial Officer
James Staveley, Head of Investor Relations
J.P.Morgan Cazenove - Nominated Adviser & Corporate
Broker
+ 44 (0) 20 7742 4000
James Mitford / Candelle Chong
FTI Consulting
+44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's eleven locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
About Spring Bioscience
Founded in 2001 by scientists with a primary focus on
immunohistochemistry (IHC), Spring Bioscience Corporation (Spring)
serves as an antibody centre of excellence, for developing and
manufacturing rabbit monoclonal antibodies designed for use in IHC.
Spring, which was acquired by Roche in 2007, has developed a
proprietary antibody menu of highly-sensitive Spring Proprietary
Clones ("SP Clones") that yield specificity and consistency for use
in research.
Forward looking statements
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAXFNFLSPEFF
(END) Dow Jones Newswires
January 22, 2018 02:00 ET (07:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024